Monday, March 9, 2009

SAVELLA FOR FIBROMYALGIA

Savella is a selective serotonin and norepinephrine reuptake inhibitor for the management of fibromyalgia.

Savella (milnacipran HCl), was approved by the FDA on January 14, 2009 and was originally expected to be available in March 2009. The companies submitted a minor post-approval cosmetic formulation change for FDA approval. A response from the FDA is anticipated no later than May, 2009. [read more]

Posted by Antonio Howell, M.D. at 3/09/2009 10:00:00 AM 0 comments

Labels: ,

Subscribe to: Posts (Atom)

Disclaimer:

This publications contains the opinions and ideas of its author(s). It is intended to provide helpful and informative material on the subjects addressed. It is written with the understanding that the author(s) is (are) not engaged in rendering medical, health, or any other kind of professional service(s). The reader should consult his or her medical, health or other competent professional before adopting any of the suggestions. The author(s) specifically disclaim all responsibility for any liability, loss, or risk, personal or otherwise, which is incurred as a consequence, directly or indirectly, of the use and application of any of the contents of this site.